Scientific reviews and scores are in for CIRM’s Disease Team III RFA.
We don’t know the identifies of the applicants yet, but 3 out of 4 of the top scoring grants recommended outright for funding are focused on cancer. As a cancer stem cell researcher (and cancer survivor) I’m excited to see how well these grants did.
The other topiscoring proposal is on macular degeneration.
The next 4 proposals, in the gray zone, are on a wide range of topics. David Jensen blogged that 3 out of 4 of these “tier two” grants also be funded. You can read more in a PowerPoint from CIRM staff here.
As yet the public does not know the names of the scientists who were the applicants. The CIRM ICOC will be meeting later this week to make final funding decisions.